Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) major shareholder Medpace Investors, Llc sold 33,000 shares of the stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $283.42, for a total transaction of $9,352,860.00. Following the sale, the insider now directly owns 5,856,947 shares in the company, valued at $1,659,975,918.74. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Medpace Investors, Llc also recently made the following trade(s):
- On Wednesday, September 20th, Medpace Investors, Llc sold 65,653 shares of Medpace stock. The stock was sold at an average price of $255.48, for a total transaction of $16,773,028.44.
- On Monday, September 18th, Medpace Investors, Llc sold 53,385 shares of Medpace stock. The shares were sold at an average price of $274.76, for a total transaction of $14,668,062.60.
Medpace Trading Down 0.3 %
NASDAQ:MEDP opened at $281.47 on Friday. The company has a market cap of $8.64 billion, a PE ratio of 32.96 and a beta of 1.37. The company has a 50 day simple moving average of $255.75 and a two-hundred day simple moving average of $242.22. Medpace Holdings, Inc. has a 12 month low of $167.00 and a 12 month high of $287.00.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on MEDP. StockNews.com started coverage on Medpace in a research report on Thursday, October 5th. They issued a “hold” rating on the stock. Guggenheim upped their price target on Medpace from $252.00 to $273.00 and gave the company a “buy” rating in a report on Tuesday, July 25th. Robert W. Baird upgraded Medpace from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $270.00 to $289.00 in a report on Tuesday, October 24th. Finally, UBS Group boosted their target price on Medpace from $215.00 to $270.00 in a research report on Wednesday, July 26th.
Hedge Funds Weigh In On Medpace
Several institutional investors have recently made changes to their positions in the business. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in Medpace during the second quarter valued at approximately $42,000. LSV Asset Management raised its holdings in Medpace by 5,285.2% in the 1st quarter. LSV Asset Management now owns 54,229 shares of the company’s stock worth $10,198,000 after purchasing an additional 53,222 shares during the period. Handelsbanken Fonder AB raised its holdings in Medpace by 46.9% in the 2nd quarter. Handelsbanken Fonder AB now owns 4,700 shares of the company’s stock worth $1,129,000 after purchasing an additional 1,500 shares during the period. Icon Wealth Partners LLC purchased a new position in Medpace during the first quarter valued at $338,000. Finally, Aviva PLC grew its holdings in Medpace by 63.0% during the first quarter. Aviva PLC now owns 7,828 shares of the company’s stock valued at $1,472,000 after purchasing an additional 3,027 shares during the period. Institutional investors own 77.98% of the company’s stock.
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
- Five stocks we like better than Medpace
- How to Buy Cheap Stocks Step by Step
- Williams-Sonoma is a steal for buy-and-hold investors
- Are Stock Buybacks Good for the Average Investor?
- A closer look at Warren Buffett’s latest surprise purchase
- Your Comprehensive Guide to Investing in Bank Stocks
- GE stock surges to six-year high: What’s behind the move?
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.